Form 4: Eli Lilly Executive Transfers Shares to Spouse in Recent Transaction

Eli Lilly's Executive Vice President and President of Lilly Oncology, Jacob Van Naarden, transferred 4,302 shares of common stock to his spouse.

Summary

• Jacob Van Naarden, an Executive Vice President at Eli Lilly, transferred 4,302 shares of Eli Lilly common stock to his spouse on October 31, 2024.
• Following the transaction, Mr. Van Naarden directly owns 11,845 shares of Eli Lilly common stock.
• He also has indirect ownership of 4,342 shares through the Van Naarden Family Trust and 4,302 shares held by his spouse.
• The transfer was a non-sale transaction, with a price of $0 per share.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding a stock transfer, which is neither positive nor negative for the company's performance.

Industry Context

This is a routine filing related to changes in beneficial ownership by a company executive, which is common in publicly traded companies. It does not indicate any significant change in the company's operations or financial health.

Comparison to Industry Standards

• Executive stock transfers are a common occurrence in publicly traded companies like Eli Lilly.
• These transactions are typically disclosed through SEC Form 4 filings, which is standard practice.
• The transfer of shares to a spouse is a personal transaction and does not reflect on the company's performance or outlook.

Related Party Transactions

• The transfer of 4,302 shares to Jacob Van Naarden's spouse is a related party transaction.

Stakeholder Impact

• This transaction has minimal impact on stakeholders as it is a personal transfer of shares by an executive.

Key Dates

Keywords

Eli Lilly, LLY, Jacob Van Naarden, stock transfer, executive, insider trading, share ownership, Lilly Oncology